Ecolab Inc. (ECL)
NYSE: ECL
· Real-Time Price · USD
261.47
0.11 (0.04%)
At close: May 20, 2025, 3:13 PM
Ecolab Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Healthcare and Life Sciences Revenue | 1.42B | 1.59B | 1.57B | 1.2B | 5.96B | 5.57B | 5.46B | 4.88B | 4.62B | 4.86B | 4.87B | 4.91B |
| Global Healthcare and Life Sciences Revenue Growth | -10.54% | +1.02% | +31.34% | -79.94% | +7.00% | +1.97% | +11.97% | +5.66% | -4.95% | -0.18% | -0.78% | n/a |
| Global Industrial Revenue | 7.78B | 7.22B | 6.94B | 6.3B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Global Industrial Revenue Growth | +7.69% | +4.00% | +10.14% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Global Institutional and Specialty Revenue | 5.38B | 5B | 4.48B | 3.98B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Global Institutional and Specialty Revenue Growth | +7.67% | +11.59% | +12.61% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 30, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.05B | 1.05B | 1.02B | 1.07B | 1.08B | 1.03B | 1.02B | 1.01B | 990.3M | 922.1M | 876.9M | 940.1M | 914.7M | 867.9M | 832M | 853.3M | 862.9M | 809.6M | 802.6M | 788.6M | 1.01B | 984M | 962.5M | 1B | 1B | 948.8M | 955.2M | 1.03B | 1.01B | 1.12B | 1.09B | 1.12B | 1.09B | 1.05B | 1.07B | 1.09B | 1.09B | 1.06B | 1.07B | 1.08B | 1.14B |
| Selling, General, and Administrative Revenue Growth | 0.00% | +2.46% | -4.37% | -0.67% | +4.25% | +0.97% | +1.31% | +2.15% | +7.40% | +5.15% | -6.72% | +2.78% | +5.39% | +4.31% | -2.50% | -1.11% | +6.58% | +0.87% | +1.78% | -22.31% | +3.15% | +2.23% | -4.01% | +0.15% | +5.52% | -0.67% | -6.97% | +1.81% | -10.27% | +3.37% | -2.51% | +2.26% | +4.23% | -2.36% | -1.98% | +0.47% | +2.78% | -1.11% | -0.79% | -5.07% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | 192M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 186M | n/a | n/a | n/a | 185M | n/a | n/a | n/a | 190M | n/a | n/a | n/a | 216M | n/a | n/a | n/a | 201M | n/a | n/a | n/a | 189M | n/a | n/a | n/a | 191M | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | n/a |